Registrant : Organisation or self-employed individual
| Name/company name: |
European Organisation for Research and Treatment of Cancer |
| Acronym: |
EORTC
|
| Legal status: |
AISBL
|
| Website address: |
http://www.eortc.org
|
Sections
| Section: |
IV - Think tanks, research and academic institutions |
| and more precisely: |
Academic institutions |
Person with legal responsibility
| Surname, Name: |
Mrs
Francoise Meunier
|
| Position: |
Director General |
Permanent person in charge of EU relations
| Surname, Name: |
Mr
Stephane Lejeune
|
| Position: |
EU Programme Coordinator |
Contact details:
| Contact details of organisation's head office: |
83 avenue Mounier
Brussels 1200
BELGIUM
|
| Telephone number: |
(+32) 27741075 |
| Fax number: |
(+) |
| Other contact information: |
|
Goals / remit
| Goals / remit of the organisation: |
Created in 1962, the European Organisation for Research and Treatment of Cancer (EORTC) is a non-profit international cancer research organisation under Belgian Law. The EORTC is recognised as scientific research institution and as non-profit clinical trial sponsor by the Belgian State. The EORTC mission is to improve the standard of cancer treatment in Europe through the development of innovative new drugs and to test more effective therapeutic strategies using commercially available drugs, surgery, or radiotherapy. The EORTC has the aim to facilitate the passage of experimental discoveries into state-of-the-art treatment by keeping to a minimum the time lapse between the discovery of new anti-cancer agents and the implementation of their therapeutic benefit for patients with cancer. This is accomplished mainly by conducting international large, multicentre, prospective, randomised, phase III clinical trials.
EORTC clinical research trials are conducted in a network of over 300 participating institutions located in 32 countries in which more than 2,900 clinicians and scientists collaborate on a voluntary basis. More than 6,000 cancer patients are entered into EORTC multidisciplinary trials each year. Some 35 EORTC trials are permanently open to patient entry. The activities of the EORTC are peer reviewed by the US National Cancer Institute. All EORTC protocols are written and conducted in accordance with international standards for ethics: the declaration of Helsinki, Good Clinical Practice guidelines approved by the International Conference on Harmonization.
Independent clinical research is the only way to guarantee an objective evaluation and to establish optimal therapeutic strategies on a multidisciplinary base. However, there is no clinical research possible without collaboration with the industry because of the need for access to innovative new drugs and funding, etc. In order to preserve EORTC independence, EORTC studies must comply with the following basic requirements 1) Clinical study protocol must undergo EORTC pee-review procedures. Input of the academics in the design and the control arm. 2) The clinical study database must be under the full control of EORTC 3) Study primary endpoints must be analysed by independent statistician and reviewed by an Independent Data Monitoring Committee 4) Study results must be published in scientific journal 5) the study bio-samples must be under the custodianship of EORTC.
Located in Brussels, the EORTC Headquarters is a unique facility in Europe. It provides scientific, legal, logistic and administrative support to the clinical and translational research activities of the EORTC cooperative groups (protocol development, data management, statistical analysis, new drugs development, translational research, physical and virtual biobanking, advanced imaging, quality of life, regulatory and ethical affairs management, training, Pharmacovigilance and Quality Assurance). The EORTC Headquarters staff is constituted by 180 highly experienced and trained professionals. Since 1991, the EORTC Fellowship Program has allowed more than 100 medical doctors, statisticians and health scientists from all over the world to do research project at the EORTC. The EORTC is offering a wide range of training for clinical research professionals ranging from GCP to clinical research methodology.
|
|
The organisation's fields of interests are:
|
|
Number of persons engaged in activities falling under the scope of the Transparency Register
| Number of persons: |
4
|
|
Complementary information:
|
|
Persons accredited for access to European Parliament premises
Activities
Main EU initiatives covered the year before by activities falling under the scope of the Transparency Register:
|
- Clinical Trials Directive 2001/20/EC
- Support to international investigator-driven clinical trials
- Human biological material for use in translational research
- Data protection
Keywords: Health, cancer, clinical research, medicine, drugs, surgery, radiotherapy, chemotherapy, imaging, laboratory, patient, pharmacovigilance, quality insurance, biostatistics, biobank, regulatory, insurances, quality of life, funding.
|
Fields of interest for e-mail alerts on consultations and roadmaps;
| Fields declared by the organisation: |
- Information Society
- Public Health
- Research and Technology
- Trans-European Networks
|
Structure
| Total number of members that are natural persons: |
2,900 |
| Number of member organisations: |
0 |
| Member organisations (Number of members) : |
|
| The organisation has members/is represented in the following country(countries): |
- AUSTRIA
- BELGIUM
- CYPRUS
- CZECH REPUBLIC
- DENMARK
- ESTONIA
- FINLAND
- FRANCE
- GERMANY
- GREECE
- HUNGARY
- IRELAND
- ITALY
- LATVIA
- LITUANIA
- LUXEMBOURG
- MALTA
- NETHERLANDS
- POLAND
- PORTUGAL
- ROMANIA
- SLOVAKIA
- SLOVENIA
- SPAIN
- SWEDEN
- UNITED KINGDOM
- AUSTRALIA
- CANADA
- CROATIA
- EGYPT
- ISRAEL
- NORWAY
- PERU
- SERBIA
- SWITZERLAND
- TURKEY
|
|
Complementary information:
|
|
Networking
Information on (i) organisation's membership of any associations/federations/confederations or (ii) relationships to other bodies in formal or informal networks.
|
European CanCer Organisation
European Forum for Good Clinical Practice
European Platform for Patients' Organisations, Science and Industry
European Association for NeuroOncology
European Association of Urology
European School of Oncology
European Association of Urology
American Association for Cancer Research
European Society for Therapeutic Radiology and Oncology
European Society for Medical Oncology
American Society for Therapeutic Radiology and Oncology
International Society of Geriatric Oncology
International Society of Pediatric Oncology
International Union Against Cancer
International Network for Cancer Research and Treatment
Organisation of European Cancer Institutes
European Oncology Nursing Society
|
Financial data
| Financial year: |
01/2010
-
01/2011
|
|
Total budget:
|
93,000
|
€
|
|
of which public financing:
|
93,000
|
€
|
|
- from European sources:
|
|
- Procurement:
|
0
|
€
|
|
- Grants:
|
93,000
|
€
|
|
- from national sources:
|
0
|
€
|
|
- from local/regional sources:
|
0
|
€
|
|
from other sources: |
0
|
€
|
|
- donations:
|
0
|
€
|
|
- contributions from members:
|
0
|
€
|
|
|
Estimated costs to the organisation directly related to representing interests to EU institutions in that year:
|
< 50000
€
|
Other (financial) information provided by the organisation:
|
The EORTC is funded through several sources including the EORTC Charitable Trust providing a core grant which is mainly supported by numerous national cancer leagues.
Since 1972, the US National Cancer Institute (NCI) has provided support to EORTC Headquarters, and with this support a close scientific collaboration has been maintained to promote transatlantic research projects.
Core grants from the Fonds Cancer, FOCA (BE) provide support for the EORTC Headquarters staff. EORTC Headquarters also receives grants allocated by BELSPO (the Belgian Federal Science Policy Office) and by the Belgian National Lottery.
Funding for the Fellowship Programme is provided by the EORTC Charitable Trust, Fonds Cancer, FOCA (BE), the Koningin Wilhelmina Fund, KWF (NL), and several leagues including La Ligue Nationale contre le Cancer (FR) and the Vlaamse Liga tegen Kanker, VLK (BE).
In addition, grants for EORTC research projects are received from the European Commission under the 6th and the 7th Framework Programmes.
The EORTC has received support for bio-banking in a prostate cancer clinical trial from the Institute for the encouragement of Institut d'encouragement de la Recherche Scientifique et de l'Innovation de Bruxelles (IRSIB).
Clinical studies evaluating new drugs for potential registration or testing innovative therapeutic agents, including some educational projects, are conducted in cooperation with pharmaceutical industry partners in strict compliance with EORTC criteria for independence. Pharmaceutical industry sponsorship is also provided in the form of “unrestricted grants” for EORTC conferences.
The finances of the EORTC include all accounts from the EORTC Headquarters as well as all EORTC Groups and Task Forces. These accounts are consolidated as required under Belgian Law. The EORTC accounts are audited by Ernst & Young.
|
|
